Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 9;2(3):203-209.
doi: 10.1002/cai2.52. eCollection 2023 Jun.

Symphony in the crowd: Key genetic alterations in prostate cancer

Neshat Masud  1
Affiliations
Review

Symphony in the crowd: Key genetic alterations in prostate cancer

Neshat Masud. Cancer Innov. .

Abstract

Androgen receptor (AR) signaling have been frequently targeted for treating prostate cancer (PCa). Even though primarily patients receive a good therapeutic outcome by targeting AR signaling axis, eventually it emerges resistance by altering the genetic makeup of prostate cells. However, to develop an effective therapeutic regime, it is essential to recognize key genetic alterations in PCa. The most common genetic alterations that give rise to distinct androgen different differentiation states are gene fusion of TMPRSS2 with ETS family genes, deletion, or mutation of tumor suppressor PTEN and TP53 gene, amplification or splicing of AR, altered DNA repair genes. In this review, we describe key genes and genetic changes that have been recognized to contribute to altered prostate environment.

Keywords: alterations; cancer; genetic; prostate cancer; symphony.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Genetic alterations in prostate cancer (PCa). PCa progresses from a recurrent inflammation of the prostatic epithelia to an aggressive form. The key genetic alterations during this conversion include: altered androgen receptor (AR), gene fusion, alteration of tumor suppressors, and defective DNA repair mechanism.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708 - DOI - PubMed
    1. Barilla S, Lindblom A, Helgadottir HT. Unravelling genetic variants of a Swedish family with high risk of prostate cancer. Hereditary Cancer Clin Pract. 2022;20(1):28. 10.1186/s13053-022-00234-0 - DOI - PMC - PubMed
    1. Thompson J, Hyytinen ER, Haapala K, Rantala I, Helin HJ, Jänne OA, et al. Androgen receptor mutations in high‐grade prostate cancer before hormonal therapy. Lab Invest. 2003;83(12):1709–13. 10.1097/01.LAB.0000107262.40402.44 - DOI - PubMed
    1. Pavel AG, Stambouli D, Gener I, Preda A, Anton G, Baston C. Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence. Sci Rep. 2022;12(1):4546. 10.1038/s41598-022-08472-x - DOI - PMC - PubMed
    1. Eeles RA, Kote‐Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–21. 10.1038/ng.90 - DOI - PubMed